Loading Events

Implementing FDA’s IVPT Guidance Recommendations: A Step-By-Step Illustration

Date and Time: April 29 , 8:30 am  –  5:30 pm ,
April 30 , 8:30 am  –  3:30 pm

Co-hosts: FDA and the Center for Research on Complex Generics (CRCG)

In person (at The Universities at Shady Grove; Rockville, MD) and virtual workshop

The In Vitro Permeation Test (IVPT) is an important performance test used by the generic drug industry to support demonstrations of bioequivalence for generic topical drug products, when utilizing efficient characterization-based bioequivalence approaches.

The workshop will clarify the intent of FDA recommendations for IVPT studies, with step-by-step demonstrations illustrating how IVPT study procedures can be performed in a manner compatible with recommendations in FDA’s Guidance for Industry: In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs. The focus will be on IVPT method procedures that abbreviated new drug application (ANDA) applicants frequently struggle to implement successfully, and the procedures will be demonstrated using different IVPT diffusion cell systems from major manufacturers. Critical considerations to guide investigators during method development, validation, and study conduct will be discussed at each stage. Also, best practices for dealing with issues that arise in different scenarios will be discussed.

Join us in person for an interactive experience featuring hands-on activities with diffusion cell systems from different manufacturers to discuss how different design features could impact how you implement FDA Guidance recommendations. Small group working sessions (only for in-person attendees) will simulate challenges and illustrate how one should navigate decisions during IVPT method development and study design for a hypothetical topical drug product. In person attendees will also have the chance to engage with regulatory, academic, and industry experts to ask questions, learn practical skills, share knowledge, and discuss how to approach challenges you may have experienced with IVPT studies. Virtual attendees will enjoy the convenience of accessing live presentations and panel sessions that discuss procedures illustrated with pre-recorded demonstrations.

Choose your experience:

Virtual Attendees will have free access to all sessions of the workshop except the small group (in-person) working sessions. Virtual attendees will be able to:
• Attend all presentations and panel discussions
• Participate in all Q&A panel discussions by submitting questions online in real time to the speakers and panelists
• Enjoy free access to workshop recordings of presentations and panel discussion (not including the small group working sessions)

In-person Attendees will enjoy all of the benefits of virtual attendance as well as interactive experiences featuring:
• Hands-on activities with diffusion cell systems from different manufacturers
• Small group working sessions simulating challenges and illustrating how one should navigate decisions during IVPT method development and study design for a hypothetical topical drug product
• Collaborative discussion and learning opportunities with FDA, academic, and industry experts

Workshop Topics

• Theoretical/conceptual understanding of the recommendations in the IVPT guidance
• Demonstration of step-by-step procedures using 4 different diffusion cell systems
• Critical considerations for method development, validation, and study conduct
• Expert guidance and best practices for overcoming challenges

Audience

This workshop is primarily designed for professionals within the pharmaceutical industry and associated contract research organizations that are involved with the design and conduct of IVPT studies. This includes pharmaceutical scientists, research and development specialists, quality assurance and quality control experts, regulatory affairs professionals and formulation and product development scientists.

Virtual Attendance is optimal for an audience who would like to have access workshop content from anywhere, eliminate travel time and expenses, and who would like to have the flexibility to attend dynamic sessions/presentations at preferred times.

In-Person Attendance is optimal for an audience that is interested in collaborative discussions and real-time engagement, immersive learning, interactive sessions and group activities.

Registration Fees:
• This workshop is FREE for virtual attendees.
• $350, in-person attendees – general
• $150, in-person attendees – government (must have an email ending in “.gov” in order to register at this rate)

For in-person attendees, beverages and food for breaks will be provided; lunch is not included. A link will be provided closer to the event for ordering lunch each day.

For faculty and students from the University of Maryland, Baltimore; The Universities at Shady Grove; and University of Michigan, the workshop is free for in-person attendance. Other students, please email us for a reduced rate. Please contact us at (info@complexgenerics.org) and indicate which workshop you are interested in.

The workshop will be held at the u003ca href=u0022https://shadygrove.umd.edu/u0022u003eu003cstrongu003eUniversities at Shady Grove (USG)u003c/strongu003eu003c/au003e.rnrnAddress: Ballroom (u003cemu003eplease follow signsu003c/emu003e), 9630 Gudelsky Drive Building II, Rockville, MD 20850

u003culu003ern tu003cliu003eTravel from local airports to Rockville, Md. (The Universities at Shady Grove (USG)) will require an Uber or Lyft, which is by far the best way to obtain car service.u003c/liu003ern tu003cliu003eAs there is road traffic in the region, the fastest way to the Shady Grove campus is the DCA airport, then taking the Metro subway from the airport to Shady Grove, then taking Uber or Lyft. Alternatively, fly into any WAS airport and take Uber or Lyft. If flying into BWI airport, we suggest taking Uber or Lyft to USG.u003c/liu003ern tu003cliu003eThe Metro subway serves DCA and IAD airports, which connects with the Shady Grove stop on the red line. If flying into IAD, taking the Metro will save some cost, but will probably take extra time, even if traffic is heavy.u003c/liu003ernu003c/ulu003ernu003cstrongu003eMore links and information:u003c/strongu003ernu003culu003ern tu003cliu003eu003ca href=u0022https://shadygrove.umd.edu/about-usg/directions-transportationu0022u003eu003cstrongu003eDirections and transportation options to USGu003c/strongu003eu003c/au003eu003c/liu003ern tu003cliu003eu003ca href=u0022https://shadygrove.umd.edu/about-usg/directions-transportation/public-transportationu0022u003eu003cstrongu003ePublic transportationu003c/strongu003eu003c/au003eu003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://shadygrove.umd.edu/sites/default/files/u81/basic-page/USG%202D%20Map%20-%207_06_22.pdfu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eCampus mapu003c/au003eu003c/strongu003eu003c/liu003ernu003c/ulu003ernu0026nbsp;

u003culu003ern tu003cliu003eThe Traville-Gateway Garage is the closest parking garage to the venue (u003cstrongu003eu003ca href=u0022https://www.complexgenerics.org/media/SOP/complexgenerics/shady-grove-parking-map.pngu0022u003eparking mapu003c/au003eu003c/strongu003e)u003cstrongu003e.u003c/strongu003e Attendees may also park in the Shady Grove Garage but will need to allow more walking time to reach the event.u003c/liu003ern tu003cliu003ernu003cdivu003eVisitor Parking: Levels 2-6 of Traville Gateway Garage. PLEASE NOTE: The ground floor of Traville Gateway Garage requires a USG employee permit at all times.u003c/divu003eu003c/liu003ern tu003cliu003eGuests are responsible for the cost of parking; parking will not be validated. Parking is $15 for all day.u003c/liu003ernu003c/ulu003ernClick for u003ca href=u0022https://shadygrove.umd.edu/about-usg/directions-transportation/parkingu0022u003eu003cstrongu003eparking informationu003c/strongu003eu003c/au003e from the USG website.

Please click on the following u0022all transportation optionsu0022 links to find transportation from the airport via subway, bus, taxi, car, and town car.rnu003culu003ern tu003cliu003eReagan National Airport (DCA): 21.1 miles from Rockville, Md. (u003ca href=u0022https://www.rome2rio.com/s/Reagan-Washington-Airport-DCA/Rockville?source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLcyy7zQozMbmmFpJCht7V5khU-X3bfr2soXFGfS0em3lADxGwG9sN0aArAyEALw_wcBu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003eall transportation options from DCAu003c/strongu003eu003c/au003e) (u003ca href=u0022https://www.rome2rio.com/map/Reagan-Washington-Airport-DCA/Rockville?source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLcyy7zQozMbmmFpJCht7V5khU-X3bfr2soXFGfS0em3lADxGwG9sN0aArAyEALw_wcB#r/Subwayu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003etrain options from DCAu003c/strongu003eu003c/au003e)u003c/liu003ern tu003cliu003eDulles International Airport (IAD): 27.8 miles from Rockville, Md. (u003ca href=u0022https://www.rome2rio.com/s/Washington-Dulles-Airport-IAD/Rockville?source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLcY1Bn3sf8YtoWhzD4xWGza_huRkf4Xg5fkFa8gX4UgJXtGAEIkvacaAk2KEALw_wcBu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003eall transportation options from IADu003c/strongu003eu003c/au003e) (u003ca href=u0022https://www.rome2rio.com/map/Washington-Dulles-Airport-IAD/Rockville?source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLcY1Bn3sf8YtoWhzD4xWGza_huRkf4Xg5fkFa8gX4UgJXtGAEIkvacaAk2KEALw_wcB#r/Subwayu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003etrain options from IADu003c/strongu003eu003c/au003e)u003c/liu003ern tu003cliu003eBaltimore/Washington International Thurgood Marshall Airport (BWI): 37.5 miles from Rockville, Md. (u003ca href=u0022https://www.rome2rio.com/s/Baltimore-Airport-BWI/Rockville?source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLfr4tJsm8lyehKLxUWCDd37DOw5KAlFJcrBdeOkMpmfYHiPpLU2Q9kaAu-SEALw_wcBu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003eall transportation options from BWIu003c/strongu003eu003c/au003e) (u003ca href=u0022https://www.rome2rio.com/map/Baltimore-Airport-BWI/Rockville?r2r_campaign=TQ_TP_Transportu0026amp;source=adwordsu0026amp;gclid=Cj0KCQiA_bieBhDSARIsADU4zLf11hqnfWf-IWVoi4n6rO_S8GrvBRmUbsfQl1jXu-er2h_AIfObX-waAr4sEALw_wcB#r/Train-subwayu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003etrain options from BWIu003c/strongu003eu003c/au003e)u003c/liu003ernu003c/ulu003e

u003culu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.omio.com/trains/washington-dc/baltimore-mdu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eTrain tickets (Omio)u003c/au003eu003c/strongu003eu003c/liu003ern tu003cliu003eWashington, DC to Baltimore: Approximately 35 minutesu003c/liu003ern tu003cliu003ePenn Station Marc SB (Baltimore): Approximately 41 miles from campusu003c/liu003ernu003c/ulu003e

Bob’s Limo Service (u003cstrongu003eu003ca href=u0022mailto:Limobobs@gmail.comu0022u003eEmailu003c/au003eu003c/strongu003e): 301-525-2525rnrnBu0026amp;B Executive Sedan (u003ca href=u0022mailto:evansgyawu@hotmail.comu0022u003eu003cstrongu003eEmailu003c/strongu003eu003c/au003e): 240-533-6262rnrnEast Coast Limousine (u003ca href=u0022mailto:eclimousine@gmail.comu0022u003eu003cstrongu003eEmailu003c/strongu003eu003c/au003e): 301-527-0413 or 240-793-8196rnrnUber: u003cstrongu003eu003ca href=u0022https://www.uber.com/global/en/cities/baltimore/u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eBaltimoreu003c/au003eu003c/strongu003e, u003cstrongu003eu003ca href=u0022https://www.uber.com/global/en/r/routes/bwi-to-rockville-md/u0022u003eBWI Airportu003c/au003eu003c/strongu003e, u003cstrongu003eu003ca href=u0022https://www.uber.com/global/en/cities/washington-dc/u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eWashington, DCu003c/au003eu003c/strongu003e, u003ca href=u0022https://www.uber.com/global/en/airports/iad/u0022u003eu003cstrongu003eDulles (IAD) Airportu003c/strongu003eu003c/au003e

u003cemu003eGuests should mention they are attending a conference at Universities of Shady Grove; most hotels offer discounts.u003c/emu003ernrnThere are many hotels within a short driving distance to the USG campus including:rnu003culu003ern tu003cliu003eu003ca href=u0022https://www.hilton.com/en/hotels/dcarvgi-hilton-garden-inn-rockville-gaithersburgu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eu003cstrongu003eHilton Garden Inn Rockville-Gaithersburgu003c/strongu003eu003c/au003e (u003ca href=u0022https://www.hilton.com/en/attend-my-event/characterizationofcomplexexcipients/u0022u003ebook using our reduced rateu003c/au003e by Dec. 10, 2023)rn14975 Shady Grove Road, Rockville, MD 20850 (0.6 miles from USG)rn240-507-1800u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.hilton.com/en/hotels/rvchmhw-homewood-suites-rockville-gaithersburgu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eHomewood Suites by Hilton Rockville-Gaithersburgu003c/au003eu003c/strongu003ern14975 Shady Grove Road, Rockville, MD 20850 (0.6 miles from USG)rn240-507-1900u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.marriott.com/en-us/hotels/wasrv-courtyard-rockvilleu0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eCourtyard by Marriott Rockvillernu003c/au003eu003c/strongu003e2500 Research Boulevard, Rockville, MD 20850 (0.9 miles from USG)rn301-670-6700u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.choicehotels.com/maryland/rockville/sleep-inn-hotels/md619u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eSleep Inn Rockvilleu003c/au003eu003c/strongu003ern2 Research Ct., Rockville, MD 20850 (1.2 miles from USG)rn301-507-8000u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.wyndhamhotels.com/en-ca/ramada/rockville-maryland/the-rockville-hotel-a-ramada/overview?CID=LC:RA::GGL:RIO:National:49872u0026amp;iata=00093796u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eThe Rockville Hotel, a Ramada by Wyndhamu003c/au003ernu003c/strongu003e3 Research Ct., Rockville, MD 20850 (1.2 miles from USG)rn301-202-1098u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.marriott.com/en-us/hotels/wasgt-springhill-suites-gaithersburg/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eSpring Hill Suites by Marriott Gaithersburgu003c/au003ernu003c/strongu003e9715 Washingtonian Blvd, Gaithersburg, MD 20878 (1.4 miles from USG)rn301-987-0900u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.marriott.com/en-us/hotels/wasvs-sheraton-rockville-hotel/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eSheraton Rockville Hotelu003c/au003ernu003c/strongu003e920 King Farm Blvd, Rockville, MD 20850 (1.4 miles from USG)rn240-912-8200u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.marriott.com/en-us/hotels/wascg-courtyard-gaithersburg-washingtonian-center/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eCourtyard by Marriott Gaithersburg Washingtonian Centeru003c/au003ernu003c/strongu003e204 Boardwalk Place, Gaithersburg, MD 20878 (1.6 miles from USG)rn301-527-9000u003c/liu003ern tu003cliu003eu003cstrongu003eu003ca href=u0022https://www.choicehotels.com/maryland/gaithersburg/comfort-inn-hotels/md413u0022 target=u0022_blanku0022 rel=u0022noopeneru0022u003eComfort Inn Shady Grove-Gaithersburg-Rockvilleu003c/au003ernu003c/strongu003e16216 Frederick Rd., Gaithersburg, MD 20877 (2.2 miles from USG)rn301-330-0023u003c/liu003ernu003c/ulu003e

Introduction to the Workshop

This 2-day hybrid (virtual and in-person) workshop is focused on addressing current challenges with the design and conduct of IVPT studies and will include discussions and hands-on demonstrations of step-by-step procedures illustrating how IVPT method procedures can be performed using different IVPT diffusion cell systems from major manufacturers.

DAY 1

Session 1: Current status and challenges with IVPT studies

Format: Presentations and a Panel Discussion with Q&A (Virtual and In-Person Attendees)

In this session, regulatory and industry scientists will discuss current challenges with the design, conduct, analysis and assessment of IVPT studies as a component of a characterization-based bioequivalence approach.

Session 2: How to develop an IVPT method – Theoretical understanding and hands on demonstrations

Format: Presentations, Illustrative videos, and a Panel Discussion with Q&A (Virtual and In-Person Attendees)

This session will include presentations from FDA laboratories on their approach to IVPT method development, along with recorded demonstrations of suitable IVPT study procedures, and common pitfalls to avoid during IVPT method development, using different diffusion cell equipment from multiple manufacturers.

Session 3: In-Person activities

Format: Small Group Working Sessions (In-Person Attendees Only)

Small group working sessions will work through hypothetical scenarios that provide attendees the opportunity for more in-depth discussion and collaboration with experts on IVPT method development, validation and data analysis.

DAY 2

Session 1: Considerations related to the analysis of IVPT data

Format: Presentations and a Panel Discussion with Q&A (Virtual and In-Person Attendees)

This session will include presentations from FDA on the scientific and regulatory considerations for analysis of IVPT method validation and pivotal study data.

Session 2: Holistic Panel Discussion

Format: Panel Discussion with Q&A (Virtual and In-Person Attendees)

Following the presentations across both Day 1 and 2, this discussion will cover the lessons learned, along with identifying the areas that are most needed to address the ongoing challenges with IVPT, where the FDA can provide additional guidance

Session 3: In-Person Activities (Continued from Day 1)

Format: Small Group Working Sessions (In-Person Attendees Only)

Small group working sessions will work through hypothetical scenarios that provide attendees the opportunity for more in-depth discussion and collaboration with experts on IVPT method development, validation and data analysis.

Address:

The Universities at Shady Grove
Building II
Ballroom (main floor, follow signs)
9630 Gudelsky Drive
Rockville, MD 20850

Click for USG directions and transportation information

Attendees can only park in the following locations:  Traville-Gateway garage parking (Levels 2-6), Lot 2, and the Shady Grove garage.  PLEASE NOTE: The ground floor of Traville Gateway Garage requires a USG employee permit at all times.  If you park in other areas, you may be ticketed.

The Traville-Gateway is located right next to Building II (workshop location).

Parking is $16 for all day. Attendees are responsible for the cost of parking; parking vouchers will not be provided.

Google maps link to the workshop venue/parking garage

  • Travel from local airports to Rockville, MD. (The Universities at Shady Grove (USG)) will require an Uber or Lyft, which is by far the best way to obtain car service.
  • As there is road traffic in the region, the fastest way to the Shady Grove campus is the DCA airport, then taking the Metro subway from the airport to Shady Grove, then taking Uber or Lyft. Alternatively, fly into any WAS airport and take Uber or Lyft. If flying into BWI airport, we suggest taking Uber or Lyft to USG.
  • The Metro subway serves DCA and IAD airports, which connects with the Shady Grove stop on the red line. If flying into IAD, taking the Metro will save some cost, but will probably take extra time, even if traffic is heavy.

More links and information:

Please click on the following “all transportation options” links to find transportation from the airport via subway, bus, taxi, car, and town car.

  • Train via Omio
  • Washington DC to Baltimore: Approximately 35 minutes
  • Penn Station Marc SB (Baltimore): Approximately 41 miles from campus

Guests should mention they are attending a conference at Universities of Shady Grove; most hotels offer discounts.

There are many hotels within a short driving distance to the USG campus including:

Hotel Distance from USG Phone
Hilton Garden Inn Rockville-Gaithersburg
14975 Shady Grove Road, Rockville, MD 20850
0.6 miles 240-507-1800
Homewood Suites by Hilton Rockville-Gaithersburg
14975 Shady Grove Road, Rockville, MD 20850

Book by April 7 for this rate using the link below: https://www.hilton.com/en/attend-my-event/implementingfdaivtpguidance/

After clicking on the link, under Rooms & Rates click on the “Visit the booking rate”.  It will show a calendar for making the reservation.

0.6 miles 240-507-1900
Courtyard by Marriott Rockville
2500 Research Boulevard, Rockville, MD 20850
0.9 miles 301-670-6700
Sleep Inn Rockville
2 Research Ct., Rockville, MD 20850
1.2 miles 301-507-8000
The Rockville Hotel, a Ramada by Wyndham
3 Research Ct., Rockville, MD 20850
1.2 miles 301-202-1098
Spring Hill Suites by Marriott Gaithersburg
9715 Washingtonian Blvd, Gaithersburg, MD 20878
1.4 miles 301-987-0900
Sheraton Rockville Hotel
920 King Farm Blvd, Rockville, MD 20850
1.4 miles 240-912-8200
Courtyard by Marriott Gaithersburg Washingtonian Center
204 Boardwalk Place, Gaithersburg, MD 20878
1.6 miles 301-527-9000
Comfort Inn Shady Grove-Gaithersburg-Rockville
16216 Frederick Rd., Gaithersburg, MD 20877
2.2 miles 301-330-0023

Haydar Abdalghafor photo

Senior Research Investigator, Pharmaceutical Development Topical, Incyte Corporation 

Dr. Haydar Abdalghafor is currently serving as a Senior Research Investigator at Incyte Corporation. He finished a Master of Science in Drug Delivery and a Doctorate in Pharmaceutical Sciences from University College London, UK. Prior to joining Incyte in 2022, he gained eight years of experience at TARO Pharmaceuticals in Canada. Dr. Abdalghafor’s expertise encompasses various aspects of dermal product development, including analytical research, formulation, preformulation, and in vitro assessments such as IVRT and IVPT. Over the course of his career, Dr. Abdalghafor has contributed to multiple publications, including patents and peer-reviewed journal articles, and has played an integral role in the development of several commercially available products. 

Aaditya Bhatt photo

Director, Analytical R&D, Amneal Pharmaceuticals 

Dr. Aaditya Bhatt received his M.S. and Ph.D. degrees at St. John’s University, Queens, NY in the field of Medicinal and Pharmaceutical Chemistry. He completed his Bachleor’s in Pharmacy in India. He joined Amneal Pharmaceuticals in 2015 and served various roles which included preformulation development support, characterization studies and bioequivalence studies of complex dosage forms which include ophthalmic, topical, oral and injectable. Dr. Bhatt’s roles and responsibilities include overseeing in-vitro development programs for complex dosage forms at Amneal Pharmaceuticals. During the last few years, Dr Bhatt has been actively involved in overseeing the development and execution activities of IVPT studies of topical and transdermal dosage forms and actively corresponded with the Agency from IVPT development standpoint. 

Bryan DeBarr photo

Director, Global Pharmacology and Toxicology Lab Operations, Pharmacology and Toxicology, Viatris Inc. 

Mr. Bryan DeBarr is currently a Director for Global Pharmacology and Toxicology Lab Operations at Viatris Inc. where he has nearly 16 years of experience in the pharmaceutical industry working in both Quality Control and the Research Development aspects of drug development.  For the last 13 years, he has been part of the Global Pharmacology and Toxicology Department supporting complex product development and lifecycle management.  

Currently, he specializes in the in vitro release (IVRT) and in vitro permeation (IVPT) analytical method and assay development, validation, and testing in a GMP, GCP, and GLP compliant laboratory with a particular focus on ophthalmic, topical, and transdermal drug delivery systems. He has extensive experience in applying in vitro and ex vivo test methods to aid in the optimization, pre-clinical evaluation, comparative biowaiver testing, and post marketing support of complex drug products. 

photo of Priyanka Ghosh

Lead Pharmacologist, DTP I, ORS, OGD, FDA

Dr. Priyanka Ghosh is a lead pharmacologist within the Division of Therapeutic Performance, ORS, OGD. Her areas of expertise include products in the topical and transdermal drug delivery area. In her current role, Dr. Ghosh leads regulatory science research initiatives related to topical, transdermal, and transmucosal drug products, under the GDUFA regulatory science program. Dr. Ghosh also leads the development of general and product-specific guidances, review strategies for industry meeting requests and citizen petitions, and is the co-chair of the Bioequivalence Standards for Topicals Committee within OGD. Prior to joining FDA, Dr. Ghosh completed her Bachelor’s degree in Biotechnology from West Bengal University of Technology (India) and a Ph.D. in Pharmaceutics and Drug Design from the University of Kentucky.

Kevin Hamman photo

President and CEO, Logan Instruments

Mr. Keith Hamman is the President and CEO of Logan Instruments, a US manufacturer of diffusion, dissolution, inhalation, and permeation testing instruments based in New Jersey. He earned his Bachelor of Science in Business Administration & Management Information Systems from California State University, Northridge before launching an I.T. startup company in Southern California in 2000. In 2007 his startup was acquired, and he was hired by Hanson Research to serve as their I.T. Director. In 2010 he was promoted to President & COO. In 2016 Teledyne Technologies acquired Hanson and Keith was later promoted to VP & General Manager of Teledyne Labs, a large group of laboratory instrument businesses. In late 2024 Keith joined Logan Instruments as the next-generation leader to accelerate new product development and bring higher technology tools to the pharma and research environments. Keith is a hands-on guy, often found in the engineering lab trying to find ways to improve the products. He really enjoys visiting customers to understand their challenges while also ensuring they’re fully supported. When he’s not working you can find him on the golf course or watching the Dodgers win another championship.

John Heaney photo

General Manager, PermeGear, Inc.

Mr. John Heaney currently is the Research and Technical Specialist at PermeGear, Inc.  He began his career with Hanson Research (now Teledyne Hanson) as a field service engineer providing installation, qualification, maintenance, and technical support for diffusion and dissolution equipment. He was later transferred to the engineering team as his direct customer experience and expertise with common issues provided valuable insight into the development of new equipment including the Phoenix Dry Heat Systems. He later served at PermeGear in the role of Research and Technical specialist providing the same expertise as well as developing methods to test customer products. After working at Quality Lab Accessories as both an Application Specialist and the Quality Manager, John returned to PermeGear and runs the day to day operations as the General Manager. 

photo of Ying Jiang

Chemist, DTP I, ORS, OGD, FDA

Dr. Ying Jiang is currently a Staff Fellow (Chemist) in the Dermal, Transdermal and Transmucosal Products Team in Division of Therapeutic Performance I (DTP I), Office of Research and Standards (ORS), Office of Generic Drugs (OGD) in FDA. In her current role, Dr. Jiang addresses specific questions and develops guidances related to therapeutic equivalence demonstration to support development of generic products in her area of expertise. She also engages in regulatory science research initiatives related to these products. Dr. Jiang obtained her Ph.D. in Pharmaceutics Sciences (topical and transdermal delivery) from Mercer University. 

Abhishek Juluri photo

Reviewer, DB III, OB, OGD, FDA

Dr. Abhishek Juluri joined the FDA in 2019 and is currently a reviewer at the Division of Bioequivalence at the Office of Generic Drugs. He earned his bachelor’s degree in pharmacy from Kakatiya University in 2009. He later earned his Ph.D. in Pharmaceutical Sciences from The University of Mississippi in 2014. He began his professional carrier as Senior Scientist at an early stage biotech company based in Akron, Ohio, where he worked on the development of novel drug delivery technology for topical and transdermal delivery of macromolecules. Later he worked as a Principal Scientist at Tergus Pharma, a Topical CRO based in Durham, NC. His research interests include topical and transdermal drug product development. 

Nahid Kamal photo

Research Pharmacologist and CMC Assessor, DPQR V, OPQR, OPQ, FDA

Dr. Nahid Kamal is a Research Pharmacologist and CMC Assessor at the Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). She earned her Bachelor of Pharmacy from the University of Science and Technology Chittagong, Bangladesh, and her Ph.D. in Pharmaceutical Sciences from Long Island University, New York. As a Principal Investigator and Subject Matter Expert in complex drug delivery systems, Dr. Kamal leads cutting-edge research on transdermal, topical, microneedle, implant, and intravaginal drug products. Her work focuses on understanding drug substances, excipients, formulations, and process parameters, evaluating in vitro and in vivo performance through advance analytical methods for complex generics and developing control strategies to ensure product quality and therapeutic performance. Dr. Kamal has made significant contributions to the FDA’s regulatory science initiatives, particularly in the evaluation of complex drug products and drug-device combinations for women’s health under the GDUFA regulatory science research program. Her research has been widely published in peer-reviewed journals and has earned her multiple intramural grants and FDA awards for scientific excellence. 

Theo Kapanadze photo

CSO, Diteba Inc

Dr. Theo Kapanadze has extensive experience in analytical R&D chemistry, the pharmaceutical, biopharmaceutical, and nutraceutical industries. As the Co-founder and Chief Scientific Officer of Diteba Inc., he has played a key role in establishing the company as a leader in Dermal and Transdermal Research Services. Under Dr. Kapanadze’s guidance, Diteba has established a strong track record in characterizing topically applied products and possesses superior scientific expertise in in vitro release test (IVRT), in vitro permeation test (IVPT). The in vitro methodologies developed at Diteba have contributed to numerous innovator and generic drug approvals.

Preceding his tenure at Diteba, Dr. Kapanadze held roles as a Research Scientist at Biovail Inc., Patheon Inc., and Taro Pharmaceuticals Inc., amassing significant expertise in pharmacokinetics and the progression of drug development through quality attributes for commercialization, encompassing both small and large molecules across various dosage forms.

With a Ph.D. and D.Sc. in Chemistry of Biological Active Compounds, along with 20+ years of research experience, Dr. Kapanadze has played an essential role in driving the success of these organizations through a plethora of publications, presentations, and collaborations within the industry. Dr. Kapanadze’s contributions have been pivotal in advancing drug development and securing numerous innovator and generic drug approvals.

Megan Kelchen photo

Senior Pharmacologist, DTP I, ORS, OGD, FDA

Dr. Megan Kelchen is a senior pharmacologist in the Division of Therapeutic Performance I (DTP I) in FDA’s Office of Generic Drugs (OGD). Her specialization is drug products for topical, transdermal, and transmucosal drug delivery. Dr. Kelchen is responsible for the development of product-specific guidances for generic drug development, reviewing and responding to controlled correspondences, citizens petitions, and pre-ANDA meeting requests. Dr. Kelchen is also engaged in regulatory science research initiatives related to complex generics under the GDUFA regulatory science research program. Dr. Kelchen received her B.A. degree in Biology from Wartburg College and her Ph.D. in Clinical Pharmaceutical Sciences from the University of Iowa.  

Headshot of Robert Lionberger

Director, ORS, OGD, FDA

Dr. Robert Lionberger serves as Director of the Office of Research and Standards (ORS) in the Office of Generic Drugs (OGD).  Dr. Lionberger leads OGD’s implementation of the Generic Drug User Fee Amendments (GDUFA) science and research commitments including internal research activities and external research grants and collaborations to ensure the therapeutic equivalence of generic drug products. ORS also provides pre-submission advice on complex generics through pre-Abbreviated New Drug Application (ANDA) meetings, product-specific guidance, and correspondence responses.    

He received his undergraduate degree from Stanford University in Chemical Engineering, and a Ph.D. from Princeton University in Chemical Engineering. After his Ph.D., he conducted post-doctoral research in Australia in the Department of Mathematics and Statistics at the University of Melbourne. Prior to joining the FDA 18 years ago, Dr. Lionberger was an Assistant Professor of Chemical Engineering at the University of Michigan. 

headshot of Markham Luke

Director, DTP I, ORS, OGD, FDA

Dr. Markham C. Luke serves as FDA Supervisory Physician (Dermatology) and Director of the Division of Therapeutic Performance 1 (DTP I) in the Office of Research and Standards, Office of Generic Drugs at FDA. DTP I is responsible for facilitating pre-application development of generic drugs by conducting and promoting regulatory science research to establish standards to ensure therapeutic equivalence of new generic drug products. Markham has an M.D. and a Ph.D. in Pharmacology from Johns Hopkins University and completed his dermatology residency and fellowship at Washington University, St. Louis, MO and the  National Institutes of Health, Bethesda, MD. He is an Associate Professor at the Uniformed Services University of the Health Sciences, Bethesda, MD with research interests in dermatopharmacology, clinical pharmacology, clinical study design and endpoints assessment (including patient-reported outcomes) for medical, surgical, and aesthetic products.  Markham has been at FDA since 1998 serving various roles, including as the Lead Medical Officer for dermatology drugs, Chief Medical Officer and Deputy Director for the Office of Device Evaluation in the Center for Devices and Radiologic Health, and as Acting Director for Cosmetics in the Center for Food Safety and Applied Nutrition.  

S, Narasimha Murthy 2025

Chief Scientific Officer, Topical Products Testing LLC, MS, USA

Dr. S. Narasimha Murthy is the Chief Scientific Officer of Topical Products Testing (TPT) LLC, USA (www.TopicalProductsTesting.com ). He is a former Professor of Pharmaceutics and Drug Delivery at the University of Mississippi for over 16 years. Dr. Murthy is a pioneer in topical and transdermal drug delivery technologies. His research programs are funded by NIH, USFDA, and pharmaceutical companies. Dr. Murthy has published over 150 research papers and presented over 250 scientific posters at national and international scientific meetings. He has authored two books and over twenty book chapters.  

Dr. Murthy has received several awards, such as the New Investigator award and Cumberland Researcher of the Year from the University of Mississippi and the Global Indus Technovator award from MIT; He was inducted as a Fellow of the American Association of Pharmaceutical Scientists in 2017.  He was bestowed with the Distinguished Scientist award by the American Association of Indian Pharmaceutical Scientists in 2018. Dr. Murthy was honored with the prestigious 2022 AAPS Pharmaceutical Global Health Award. In 2023, the Academy of Pharmaceutical Sciences, UK, awarded him a Fellowship, which is the highest award given to very few selected members recognizing their research accomplishments in any sector of pharmaceutical sciences.   Dr. Murthy is also one of the co-founders of a non-profit research organization in India, “The Institute for Drug Delivery and Biomedical Research (IDBR)” (www.IDBResearch.com), founded in 2013.  

Mengmeng Niu photo

Senior Pharmacologist, DTP I, ORS, OGD, FDA

Dr. Mengmeng Niu is a Senior Pharmacologist within the Division of Therapeutic Performance I (DTP I) in the Office of Research and Standards (ORS), Office of Generic Drugs (OGD) at FDA. Her work involves regulatory reviews and product specific guidance development for topical and transdermal drug products. Prior to joining FDA, she is an associated scientific liaison with U.S. Pharmacopeia. Dr Niu graduated in 2011 with a Ph.D. degree in pharmaceutical science, followed by two years of postdoctoral training at University of Texas at Austin and one-and-half year’s research and development work in industry on topical and transdermal products. 

Ashvin Patel photo

Director of Analytical Research, Teledyne Hanson Research

Dr. Ashvin Patel is working as Director of Analytical Research at Teledyne Hanson Research, part of Teledyne Labs since 2017. He has been in pharmaceutical industry for over 25 years. Dr. Patel obtained his Ph.D. in Chemistry from Veer Narmad South Gujarat University (India) in 1997. Prior to joining Teledyne, he held various positions with increasing responsibilities in large pharmaceuticals companies. He successfully led analytical laboratories to manage multiple research projects and team of talented scientists. Dr. Patel’s expertise and knowledge in analytical chemistry helped many pharmaceutical companies to file ANDA successfully, and many other regulatory submissions.     

He loves to work on analytical instruments and help customers to solve their problems. Dr. Patel likes to play and watch cricket. He is also helping a non-profit organization which helps stray animals in rural part of India, Northern Canada, and USA.   

Hiren Patel photo

Senior Staff Fellow, DB II, OB, OGD, FDA

Dr. Hiren Patel is a bioequivalence assessor in the Division of Bioequivalence II within Office of Generic Drugs (OGD). Prior to joining FDA, he earned his M.S. and Ph.D. with specialization in Pharmacokinetics at Long Island University, Brooklyn, New York. At U.S. FDA, he is responsible for assessing the bioequivalence of the various dosage forms of generic drugs. He is the lead for the topical and transdermal drug products and the advanced techniques for demonstrating bioequivalence of such complex drug products within the Office of Bioequivalence. He is the co-chair for Bio-Equivalence Standards for Topicals (BEST) Expert Committee within OGD. He has also actively served as a consultant in the research initiatives which are the collaborative efforts of FDA and global research institutions pertaining to the topical and transdermal drug products funded through FDA. Dr. Patel is also actively involved in the review panel for the Product Specific Guidance for the generic topical drug products. 

Headshot of James Polli

Co-Director of CRCG, Professor of Pharmaceutical Sciences, Ralph F. Shangraw/Noxell Endowed Professor, Industrial Pharmacy and Pharmaceutics, University of Maryland

Dr. James Polli is Ralph F. Shangraw/Noxell Endowed Professor in Industrial Pharmacy and Pharmaceutics at University of Maryland. His research interest is oral drug absorption, involving laboratory and clinical research. He has served as the advisor to 25 Ph.D. graduates. He is co-Director of the University of Maryland Center of Excellence in Regulatory Science and Innovation and the Center for Research on Complex Generics, each an FDA-funded collaborative agreement with the Agency. He is Director of the online M.S. in Regulatory Science program. He is a fellow of the American Association for Pharmaceutical Scientists (AAPS) and served as an editor of Pharmaceutical Research for 12 years. He is the 14th recipient of the American Pharmacists Association Takeru Higuchi Research Prize. He was the recipient of the 2024 American Association of Colleges of Pharmacy Volwiler Research Achievement Award, the 2022 AAPS Global Leadership Award, and the 2021 TOPRA Education Award. He is a member of the University of Maryland General Clinical Research Center Advisory Committee and the University of Maryland institutional review board (IRB). 

Lakshmi Raghavan photo

Founder and CEO, Healios Labs LLC

Dr. Lakshmi Raghavan is a successful, serial entrepreneur with more than 25 years of technical and business development expertise. Lakshmi Raghavan is currently the Founder and CEO of Healios Labs LLC, leading its overall corporate strategy and Business Development and R&D. Prior to Healios Labs, Dr. Raghavan founded Solaris Pharma Corporation in 2015, a company dedicated to developing generic and branded pharmaceutical products, from concept to commercialization primarily in topical and ophthalmic products. He has been instrumental and has a distinguished track record of obtaining FDA approvals using in vitro methodologies including IVRT and IVPT techniques. Dr. Raghavan also founded DermPathe Pharmaceuticals in 2010, a contract research organization providing contract research & development services in development of non-solid oral dosage forms, taking products from concept to clinical.  

Prior to DermPathe Pharmaceuticals, Dr. Raghavan led the R&D at Vyteris Corporation for six years, where he was responsible leading all its R&D programs based on its iontophoretic transdermal technology. 

Dr. Raghavan holds a Master of Science in Physics from the University of Madras, Chennai, India and a Doctor of Philosophy degree in Physics from Indian Institute of Technology, Chennai, India. He has more than 40 research publications and eight book chapters.  

Tannaz Ramezanli photo 2025

Senior Pharmacologist, DTP I, ORS, OGD, FDA

Dr. Tannaz Ramezanli is a senior pharmacologist within the Office of Research and Standard (ORS) at Office of Generic Drugs (OGD) at the U.S. FDA. She specializes in topical, transmucosal, and transdermal products. She is responsible for the development of product-specific bioequivalence guidances, reviewing and responding to controlled correspondences, citizen petitions, and industry meeting requests. She also leads multiple regulatory science research initiatives related to development of bioequivalence standards for complex topical drug products through FDA-funded collaborations with research institutions around the world. She received her Ph.D. in Pharmaceutical Sciences from Rutgers University and her Pharm.D. from Tehran University of Medical Sciences. 

Associate Director for Science & Chief Scientific Advisor, ORS, OGD, FDA

Dr. Sam Raney is the Associate Director for Science and Chief Scientific Advisor in the FDA’s Office of Research and Standards and Office of Generic Drugs, where he oversees the research portfolio of FDA’s generic drug research program. He has over 30 years of experience in pharmaceutical drug development, specializing in topical and transdermal products, and producing numerous research manuscripts, review articles, book chapters and patents. He has been a researcher and adjunct professor within academia, was the longest serving Chair of the AAPS Topical and Transdermal Community, has been a principal or sub investigator on over 400 pharmaceutical product studies, has held senior management roles in industry, serves on multiple expert committees and panels for the U.S. Pharmacopeia, and is frequently invited to speak at scientific meetings around the world. Dr. Raney holds a Bachelors Degree in Molecular Biophysics & Biochemistry from Yale University, and a Ph.D. in Biochemistry & Molecular Biology from the University of British Columbia in Canada.  

Elena Rantou photo

Master Mathematical Statistician, DB VIII, OB, OTS, FDA

Dr. Elena Rantou is a Master Scientist in the Office of Biostatistics/OTS/CDER. She joined FDA in 2013. Since 2019 she is a lead mathematical statistician working with generic and biosimilar products.  Her research work is mainly focused on assessing bioequivalence of topical/dermatological generic products, characterizing outliers in replicate PK studies, the detection of data anomalies and the use of AI/ML in drug development.  She has contributed to various working groups and worked towards guidance development. She is part of the leadership of the FDA Modeling and Simulation working group and co-chairs the AI/ML and the digital health technologies (DHT) Regulatory Review Committee in the Office of Biostatistics. 

Elena holds a Ph.D. from American University, Washington, DC and prior to joining the FDA, she worked in the academia and as a statistical consultant for over 15 years. 

Allison Schafer photo

Senior Interdisciplinary Scientist, DB II, OB, OGD, FDA

Dr. Allison Schafer is a Senior Interdisciplinary Scientist in the Office of Bioequivalence, Office of Generic Drugs, at the U.S. Food and Drug Administration. In this role, she reviews and evaluates the results of clinical and non-clinical pharmacological studies on various dosage forms submitted by generic drug sponsors in support of abbreviated new drug applications (ANDAs) to assess the relative pharmacology of the drug products. Prior to joining the FDA, Dr. Schafer received her Ph.D. in Pharmaceutical Sciences from the University of Michigan and a B.Sc. in Biochemistry with a concentration in Medicinal Chemistry from Arizona State University. 

Headshot of Anna Schwendeman

Co-Director of CRCG, Larry and Ann Hsu Professor of Pharmacy, Chair, Department of Pharmaceutical Sciences, Biointerfaces, College of Pharmacy, University of Michigan

Dr. Anna Schwendeman is a Larry and Ann Hsu Collegiate Professor and Chair of the Department of Pharmaceutical Sciences at the University of Michigan. Her research focus is on optimization of high-density lipoprotein (HDL) nanoparticles for treatment of atherosclerosis, sepsis, and drug delivery purposes. In 2016, she co-founded a company EVOQ Therapeutics (www.evoqtherapeutics.com) focused on the use of HDL Nanodiscs for delivery of personalized neoantigen cancer vaccines. Dr. Schwendeman received her B.S. from Moscow Institute of Physics and Technology and Ph.D. in Pharmaceutics from The Ohio State University. Prior to starting her academic career in 2012, Dr. Schwendeman spent 12 years in the pharmaceutical industry at Cerenis Therapeutics, Pfizer, and Esperion Therapeutics. She was involved in discovery and translation HDL drugs to clinical trials. She successfully submitted FDA INDs for seven different products including nanoparticles, liposome, recombinant proteins, peptides, and small molecules. Her laboratory’s research in regulatory sciences is focused on analytical characterization of liposomes, polymer microspheres, peptides, and biosimilar products. She is co-Director of FDA sponsored Center for Research in Complex Generics (http://www.complexgenerics.org). Dr. Schwendeman is an Associate Editor for Nanomedicine NBM and Eur. J. Pharm and Biopharm.

photo of Audra Stinchcomb

Professor, School of Pharmacy, University of Maryland Baltimore

Dr. Audra Stinchcomb is a translational researcher and serial entrepreneur. Her breadth of research includes pharmaceutics, drug delivery, pharmacokinetics, complex drug product development, clinical trial optimization, regulatory science, and public-private partnership maximization. She has a B.S. in Pharmacy from the University of Colorado, a Ph.D. in Pharmaceutics and Drug Delivery from The University of Michigan, and a postdoc at the University of California, San Francisco. Dr. Stinchcomb is a fellow of the American Association of Pharmaceutical Scientists and of the American Institute for Medical and Biological Engineering.

Headshot of Eleftheria Tsakalozou

Senior Pharmacologist, DQMM, ORS, OGD, FDA

Dr. Eleftheria Tsakalozou joined the FDA in 2015 as an Oak Ridge Institute for Science and Education (ORISE) Fellow. She is currently a Senior Pharmacologist at the Division of Quantitative Methods and Modeling at the Office of Research and Standards with expertise on physiologically-based pharmacokinetic modeling and simulation approaches for topical and transdermal drug products. Dr. Tsakalozou obtained her Ph.D. in Pharmaceutical Sciences at the University of Kentucky in 2013 and completed a two-year Fellowship in Clinical Pharmacokinetics and Pharmacodynamics at the University of North Carolina at Chapel Hill. Her research interests also include the development of quantitative modeling and simulation tools to support bioequivalence assessments and the interactions between inactive ingredients and molecular targets including gut transporters. 

Rong Wang photo 2025

Supervisory Associate Director, DB I, OB, OGD, FDA

Dr. Rong Wang is currently the Supervisory Associate Director in Division of Bioequivalence I (DBI), Office of Bioequivalence (OB), Office of Generic Drugs (OGD). Dr. Wang embarked on her regulatory science career at Food and Drug Administration (FDA) in 2010 and has since gained over 14 years of extensive experience within OGD. Throughout her tenure, Dr. Wang has served as a primary, secondary and tertiary assessor of abbreviated new drug applications (ANDAs), Control Correspondences (CCs), Protocols and various other generic drug related regulatory submissions. Dr. Wang has played an active role in various working groups within the Agency where she has contributed her expertise and experience in revising or developing general guidance for ANDAs and establishing work process for ANDA assessment. Dr. Wang has been actively involved in the Bio-Equivalence Standards for Topicals (BEST) Expert Committee within OGD, focusing on addressing key challenges identified from ANDA submissions of topical dermatological products.  Dr. Wang received her undergraduate degree in pharmacy from Shanghai Medical University and her Ph.D. in Microbial and Biochemical Pharmaceutical Science from the Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College. Dr. Wang also holds a Pharm.D. degree from the University of Florida. 

Yang Yang photo

Research Staff Fellow, DPQR V, OPQR, OPQ, FDA

Dr. Yang Yang is a research staff fellow at FDA-CDER-Office of Pharmaceutical Quality. She has more than 10 years of experience leading research teams to conduct regulatory research on complex drug products, including sunscreens, dermatological and topical products, abuse-deterrent opioids, nasal and inhalation drug products, etc. Her work involves formulation and manufacturing process development and evaluation, bioanalytical and product characterization, in vivo testing and bio-predictive modeling, guidance development, and internal consultation. Dr. Yang obtained her bachelor’s and master’s degrees in pharmaceutics from Peking University, China, and a Ph.D. degree in biopharmaceutical sciences from the University of Illinois at Chicago. 

 

photo of Ahmed Zidan

Senior Research Pharmacologist, DPQR V, OPQR, OPQ, FDA

Dr. Ahmed Zidan is a senior pharmacologist staff at the Division of Product Quality Research in the Office of Testing and Research of CDER. Ahmed leads the topical and transdermal drug products laboratories of DPQR and provides hands-on training to reviewers on various topics, including transdermal delivery systems, in vitro release, permeation testing of pharmaceuticals, and preformulation consideration for the development of topical and oral drug products. Dr. Zidan also leads OTR research efforts supporting the development of general and product-specific guidance documents, review strategies for pre-ANDAs and ANDAs, and citizen petitions for topical drug products. Ahmed is the government liaison Expert of the USP committee of complex excipients. His research activities and collaborations produced various publications and book chapters. Ahmed completed his Bachelor’s and Master’s degrees in Pharmaceutical Sciences at Zagazig University and his Doctoral degree in Drug Delivery at Howard University. 

https://www.loganinstruments.com/

Automated Transdermal Franz Cell Sampling System (Water Jacket)

Logan Instruments, with manufacturing in Somerset, NJ, is the global market leader in high quality diffusion cell testing instruments. Our products are designed to perform both IVRT & IVPT applications due to the advanced autosampling technology allowing for full or partial sampling. Many Logan models come with our bubble-free design which will purge bubbles that from under the membrane. From manual to automated, fingernail to ophthalmic, Logan has a broad portfolio to address most diffusion applications. We also offer custom services to support unique formulation challenges.

https://permegear.com/

In-Line Diffusion Cell Automated System

Franz Cell System

In 1994, PermeGear began manufacturing and marketing its own glass diffusion cells and introduced the In-Line Cell, a flow type diffusion cell accurately machined from  polychlorotrifluoroethylene.  In-Line Cells are used in PermeGear’s ILC07 Automated System.  PermeGear is recognized as a leader in the diffusion cell industry and continues to make hundreds of varieties of Franz Cells, Side-Bi-Side Cells, and In-Line Cells for the global research community.  PermeGear also provides custom diffusion cells.

https://www.teledynelabs.com/brands/hanson

Teledyne LABS Phoenix™ Dry-Heat System

Teledyne LABS comprises five Teledyne brands under one name to provide easy access and a clear understanding of our exceptionally broad range of precise, intuitive, and dependable laboratory instruments. Teledyne Hanson’s Phoenix™ ​D​ry‐Heat Systems feature an advanced design to make diffusion‐cell testing faster, easier, and more economical. Our IVPT experts work with you to determine the system that meets your needs and exceeds your expectations.

https://cyberderm-inc.com/

Cortex Technology Single Parameter USB DermaLab© System (transepidermal water loss-TEWL)

cyberDERM, inc. remains committed to providing innovative bio-instrumental instrumentation from Cortex Technology for noninvasive analysis of skin structure, its functions, and effects of topical treatments. Cortex Technology DermaLab USB single parameter units present a breakdown of the most popular parameters in our DermaLab Combo series into individual modules – based on the same technology and using the same probes.  In addition to the well known parameters for measuring TEWL, elasticity, color, and hydration, this generation also features 20 MHz high resolution skin ultrasound imaging as well as a newly developed subcutane ultrasound probe capable of visualizing layers and structures to a depth of 50 mm. It is delivered with newly revised application software running on Windows PC´s or tablets, and the same software will work with one or more modules connected to the same PC/tablet via USB.

https://delfintech.com/

VapoMeter (transepidermal water loss-TEWL); closed-chamber measurement

Delfin Technologies provides high-precision skin measurement instruments designed to support research in dermatology, pharmaceuticals, and cosmetics. The VapoMeter is a portable instrument designed for precise transepidermal water loss (TEWL) measurements, making it highly valuable for in vitro permeation testing (IVPT) studies. The VapoMeter’s closed-chamber technology eliminates the influence of ambient airflows, ensuring reproducible and accurate TEWL readings essential for validating drug penetration and skin barrier integrity. Its easiness of use, and rapid measurement capability make it a preferred choice in permeability studies and formulation development, where precise moisture flux data is crucial for regulatory compliance and product validation​.